CAZZANIGA MARINA ELENA

Cazzaniga, M., Cogliati, V., Rossi, E., Paris, I., Borella, F., Moretti, G., et al. (2026). Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY, 11(March 2026) [10.1016/j.esmorw.2025.100665]. Detail

Cazzaniga, M., Costa, L., Freyer, G., Gligorov, J., Lindman, H., Wysocki, P., et al. (2026). Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review. ONCOLOGY AND THERAPY, 14(1 (March 2026)), 95-112 [10.1007/s40487-025-00398-4]. Detail

Franco, G., Promi, S., Galbardi, I., Paciocco, G., Allegranza, P., Cangiotti, C., et al. (2026). A hypermetabolic pulmonary lesion in a patient with breast cancer. BREATHE, 22(2) [10.1183/20734735.0042-2026]. Detail

Garrigos, L., Ruiz-Borrego, M., Perez-Garcia, J., Guerrero-Zotano, A., Cortes-Salgado, A., Kuemmel, S., et al. (2026). A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study☆. ANNALS OF ONCOLOGY, 37(6), 837-848 [10.1016/j.annonc.2026.01.013]. Detail

Hurvitz, S., Layman, R., Curigliano, G., André, F., Cristofanilli, M., Kim, S., et al. (2026). VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY, 44(12), 1108-1119 [10.1200/JCO-25-02643]. Detail